Goldman Sachs vs Lexicon Pharmaceuticals Which Is More Lucrative?

Goldman Sachs and Lexicon Pharmaceuticals are two distinct companies in the financial and pharmaceutical industries, respectively. Goldman Sachs, a global investment bank, has a longstanding reputation for its financial services and diverse portfolio of investments. On the other hand, Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing innovative treatments for various diseases. Both companies' stocks have experienced fluctuations in the market, with investors closely monitoring their performance and potential for growth.

Goldman Sachs or Lexicon Pharmaceuticals?

When comparing Goldman Sachs and Lexicon Pharmaceuticals, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Goldman Sachs and Lexicon Pharmaceuticals.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Goldman Sachs has a dividend yield of 1.87%, while Lexicon Pharmaceuticals has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Goldman Sachs reports a 5-year dividend growth of 27.23% year and a payout ratio of 36.22%. On the other hand, Lexicon Pharmaceuticals reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Goldman Sachs P/E ratio at 16.07 and Lexicon Pharmaceuticals's P/E ratio at -1.97. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Goldman Sachs P/B ratio is 1.62 while Lexicon Pharmaceuticals's P/B ratio is 1.64.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Goldman Sachs has seen a 5-year revenue growth of 0.57%, while Lexicon Pharmaceuticals's is -0.99%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Goldman Sachs's ROE at 10.23% and Lexicon Pharmaceuticals's ROE at 73.27%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $596.16 for Goldman Sachs and $1.23 for Lexicon Pharmaceuticals. Over the past year, Goldman Sachs's prices ranged from $323.53 to $607.15, with a yearly change of 87.66%. Lexicon Pharmaceuticals's prices fluctuated between $0.94 and $3.73, with a yearly change of 296.81%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.